However, a phase 2 trial of binimetinib plus palbociclib versus trifluridine/tipiracil (TAS-102) unfortunately did not show significant improvement in PFS in refractory KRAS mutant CRC [63]. Here, KRAS is linked to colorectal carcinoma.